View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 28, 2021updated 12 Jul 2022 11:29am

OncoSec doses subjects in Covid-19 vaccine candidate trial

OncoSec Medical has dosed several subjects in its Phase I clinical trial of vaccine candidate with an immunostimulatory cytokine, CORVax12, for treating Covid-19.

OncoSec Medical has dosed several subjects in its Phase I clinical trial of vaccine candidate with an immunostimulatory cytokine, CORVax12, for treating Covid-19.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The CORVax12 vaccine approach combines the co-administration of OncoSec’s TAVO (tavokinogene telseplasmid) with a DNA-encodable version of the SARS-CoV-2 spike (S) glycoprotein to boost the immunogenicity of the component developed by the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center scientists.

A cancer immunotherapy candidate, TAVO is potent and well-characterised plasmid-based IL-12 cytokine.

This trial ‘CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for Covid-19 (SARS-CoV-2)’ will evaluate the safety and anti-viral immunological responses of the combination of DNA-encodable stabilised SARS-CoV-2 spike glycoprotein with TAVO.

The open-label study will enrol 36 healthy participants, who will receive CORVax12 as a prime dose and a booster dose four weeks apart.

Volunteers will be sub-divided into two parallel age groups of 18 to 55 and above 55.

CORVax12, the DNA vaccine, will be administered using the Cliniporator low-voltage gene electro-transfer platform, which was licensed exclusively in the US by OncoSec, recently.

As IL-12 provides coordinated cellular and humoral immunity, it could not only be a better vaccine but also significantly benefits cancer patients who may not mount on effective immune response using traditional vaccines.

According to the latest preclinical data, CORVax12 induced a strong immune response in mouse models by leading to the production of anti-spike IgG antibodies, which can disrupt spike protein’s receptor-binding domain.

Furthermore, CORVax12 administered into tumour tissue yields a productive anti-viral response as well as robust anti-tumour response.

OncoSec chief scientific officer Christopher Twitty said: “We are encouraged by the potential of CORVax12 as a next-generation vaccine to facilitate a long-lasting immune response.

“Immune compromised patients, such as those with cancer, may benefit from a vaccine option that not only drives an anti-tumour response but also creates lasting immunity to SARS-CoV2 by boosting their immune systems to mount a defence against Covid-19.”

Earlier, OncoSec dosed the first patient in an investigator-initiated Phase II trial, OMS-104, of Tavo in combination with Opdivo (nivolumab) as a neoadjuvant therapy before surgery in patients with operable, locally, or regionally advanced melanoma.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena